Our findings reveal a novel mechanism by which VSG alleviates MASLD through gut microbiota-dependent activation of intestinal FXR, offering new perspectives for microbiome-targeted therapeutic strategies in MASLD. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.